IN THE CLAIMS

- 1. (canceled)
- 2. (previously presented) A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases, and urological diseases in a mammal, comprising the steps of
 - i) determining activity of a PRSC1 polypeptide at a certain concentration of a test compound or in the absence of said test compound, and
 - ii) determining the activity of said polypeptide at a different concentration of said test compound.
 - 3. (canceled)
- (currently amended) The method of elaim 1 claim 2, wherein the step of contacting is in or at the surface of a cell.
 - 5. (currently amended) The method of elaim 1 claim 2, wherein the cell is in vitro.
- (currently amended) The method of elaim 1 claim 2, wherein the step of contacting is in a cell-free system.
- (currently amended) The method of elaim 2, wherein the polypeptide is coupled to a detectable label.
- (currently amended) The method of elaim 1 claim 2, wherein the compound is coupled to a detectable label.
- (currently amended) The method of elaim 1, wherein the test compound displaces a ligand which is first bound to the polypeptide.

- 10. (currently amended) The method of elaim 1 claim 2, wherein the polypeptide is attached to a solid support.
- 11. (currently amended) The method of elaim 1 claim 2, wherein the compound is attached to a solid support.
 - 12-26. (canceled)